Mirum Pharmaceuticals, Inc. specializes in the research, development, and commercialization of novel treatments for rare liver diseases. The company's flagship product, LIVMARLI (maralixibat), is an orally administered IBAT inhibitor approved in the United States and internationally for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). In addition to LIVMARLI, Mirum's commercial portfolio includes Cholbam (cholic acid) and Chenodal (chenodiol) for bile acid synthesis and peroxisomal disorders. The company's clinical pipeline features volixibat, another IBAT inhibitor targeting primary sclerosing cholangitis and primary biliary cholangitis, as well as brelovitug, a monoclonal antibody for chronic hepatitis delta virus. Operating primarily in North America and Europe, Mirum leverages strategic partnerships to expand its global footprint. The company maintains a strong competitive position in the pediatric hepatology market by focusing on high-unmet-need conditions and targeted bile acid modulation.
